Cell Immunol. 2010;264(1):7-17 Authors: Ichim TE, Harman RJ, Min WP, Minev B, Solano F, Rodriguez JP, Alexandrescu DT, De Necochea-Campion R, Hu X, Marleau AM, Riordan NH Since the days of Medawar, the goal of therapeutic tolerogenesis has been a “Holy Grail” for immunologists. While knowledge of cellular and molecular mechanisms of this process has…

Rheumatol Int. 2010 Jul 30; Authors: Bazsó A, Sevcic K, Orbán I, Poór G, Balogh Z, Kiss E Hereby, we report the case of a 12-year-old girl developing oligoarthritis and progressing into a polyarticular form. Rheumatoid factor was positive, and juvenile idiopathic arthritis (JIA) was diagnosed. After a poor response to DMARDs, an anti-TNF agent…

Arthritis Res Ther. 2010;12(4):135 Authors: Jorgensen C Based on their capacity to suppress immune responses, multipotent mesenchymal stromal cells (MSCs) are intensively studied for regenerative medicine. Moreover, MSCs are potent immunomodulatory cells that occur through the secretion of soluble mediators including nitric oxide, transforming growth factor beta, and HLAG5. The MSCs, however, are also able…

PLoS One. 2010;5(8):e12381 Authors: Nowak I, Majorczyk E, WiÅ›niewski A, Pawlik A, Magott-Procelewska M, Passowicz-MuszyÅ„ska E, Malejczyk J, PÅ‚oski R, Giebel S, Barcz E, ZoÅ„-Giebel A, Malinowski A, Tchórzewski H, Chlebicki A, Łuszczek W, Kurpisz M, GryboÅ› M, WilczyÅ„ski J, Wiland P, Senitzer D, Sun JY, Jankowska R, Klinger M, KuÅ›nierczyk P BACKGROUND: KIR2DS5 gene…